Use of Iron Isomaltoside 1000 (Monofer) in Postpartum Anemia

Postpartum Anemia Clinical Trial

Official title: Iron Isomaltoside 1000 (Monofer)

Status Completed

Clinical Trial Summary

The investigators hypothesized that both isomaltoside 1000 (Monofer), and oral iron preparation will be equally effective in correction of postpartum iron deficiency anemia.

Clinical Trial Description

Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. This preparation has been used for treatment of anemia in patients with chronic renal disease, gastrointestinal disorders, anemia of malignancy and in gynecological disorders. It does not require a test dose to be given before total dose, nor does it require any premedication. It can be given in a dose of 20mg/kg. The drug has been licensed for use in Europe in 2009. It has been used for treatment of anemia in patients with chronic renal disease, inflammatory bowel disease and in anemia due to malignancies ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Anemia
• Postpartum Anemia

• NCT number: NCT01628770
• Study type: Interventional
• Source: Dow University of Health Sciences
• Status: Completed
• Phase: N/A
• Start date: May 2012
• Completion date: December 2012